Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix™ Vaccine, in Healthy Infants and Children in Sri Lanka
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01803425|
Recruitment Status : Withdrawn (Lack of clarity regarding the PMS study requirement from the RA and Ethics committee hence it was concluded GSK will submit local PSURs.)
First Posted : March 4, 2013
Last Update Posted : September 9, 2013
|Condition or disease||Intervention/treatment|
|Immunisation Against Streptococcus Pneumoniae||Other: Synflorix™ data collection|
The participating physicians (investigators) will be asked to enrol only those subjects to whom they administer Synflorix™ in the course of their normal clinical practice according to the locally approved Prescribing Information.
Since there is lack of clarity regarding the PMS study requirement (both from Regulatory agency and Ethics Committee), it was decided that GSK will submit Local PSURs on a regular basis as desired by Local regulatory agency. The same is communicated to Regulatory agency and if they want something more they are requested to revert back with specific requirements.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Post-marketing Surveillance (PMS) of GlaxoSmithKline Biologicals' 10-valent Pneumococcal Conjugate Vaccine (Synflorix™) When Administered to Healthy Infants and Children According to the Prescribing Information in Sri Lanka|
|Study Start Date :||April 2013|
|Estimated Primary Completion Date :||April 2014|
|Estimated Study Completion Date :||April 2014|
Only those subjects to whom Synflorix™ will be administered as per normal clinical practice, according to the locally approved PI, will be included in the study.
Other: Synflorix™ data collection
Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.
- Occurrence of solicited local (any intensity) and general (any intensity and causally related) adverse events (AEs) [ Time Frame: During the 4-day follow-up period (Day 0 to Day 3) following any dose of Synflorix™ and overall ]
- Occurrence of unsolicited AEs [ Time Frame: During the 31-day period (Day 0 to Day 30) following any dose of Synflorix™ and overall ]
- Occurrence of Serious Adverse Events (SAEs) [ Time Frame: Throughout the PMS study period, starting at Dose 1 (Visit 1) and ending 31 days (Day 0 to Day 30) after the last dose of Synflorix™ for each subject in the PMS study ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01803425
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|